Proto-Oncogene Proteins c-kit
"Proto-Oncogene Proteins c-kit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
| Descriptor ID |
D019009
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.050 D12.776.543.750.630.124 D12.776.543.750.705.852.150.100 D12.776.543.750.750.400.200.170 D12.776.624.664.700.183
|
| Concept/Terms |
Proto-Oncogene Proteins c-kit- Proto-Oncogene Proteins c-kit
- Proto Oncogene Proteins c kit
- c-kit, Proto-Oncogene Proteins
- Stem Cell Factor Receptor
- SCF Receptor
- p145 c-kit
- c-kit, p145
- p145 c kit
- p145(c-kit)
- p145c-kit
- p145c kit
- CD117 Antigen
- Antigens, CD117
- CD117 Antigens
- Proto-Oncogene Protein c-kit
- Proto Oncogene Protein c kit
- c-kit, Proto-Oncogene Protein
- c-kit Protein
- c kit Protein
- kit Proto-Oncogene Protein
- Proto-Oncogene Protein, kit
- kit Proto Oncogene Protein
- Receptor, Stem Cell Factor
- Proto-Oncogene Protein kit
- Proto Oncogene Protein kit
- c-kit Receptor
- c kit Receptor
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-kit".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-kit".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-kit" by people in this website by year, and whether "Proto-Oncogene Proteins c-kit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 6 | 8 | 14 |
| 2004 | 10 | 9 | 19 |
| 2005 | 7 | 7 | 14 |
| 2006 | 8 | 8 | 16 |
| 2007 | 5 | 6 | 11 |
| 2008 | 5 | 7 | 12 |
| 2009 | 7 | 4 | 11 |
| 2010 | 5 | 15 | 20 |
| 2011 | 3 | 10 | 13 |
| 2012 | 3 | 8 | 11 |
| 2013 | 5 | 8 | 13 |
| 2014 | 4 | 7 | 11 |
| 2015 | 2 | 3 | 5 |
| 2016 | 4 | 2 | 6 |
| 2017 | 3 | 2 | 5 |
| 2018 | 4 | 5 | 9 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 6 | 7 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-kit" by people in Profiles.
-
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11?+?17/18?mutations. Future Oncol. 2024; 20(27):1973-1982.
-
Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):e878-e882.
-
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer. 2024 Apr; 71(4):e30898.
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb; 30(2):498-506.
-
A Rare PDGFRA Exon 15 Germline Mutation Identified in a Patient With Phenotypic Manifestations Concerning for GIST-Plus Syndrome: A Case Report and Review of Literature. Int J Surg Pathol. 2023 Sep; 31(6):1139-1145.
-
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. Clin Cancer Res. 2022 04 01; 28(7):1268-1276.
-
Current update on molecular cytogenetics, diagnosis and management of gastrointestinal stromal tumors. World J Gastroenterol. 2021 Nov 07; 27(41):7125-7133.
-
Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity. Leuk Lymphoma. 2022 01; 63(1):235-238.
-
Avapritinib for Systemic Mastocytosis. Expert Rev Hematol. 2021 08; 14(8):687-696.
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.